A ceremony has been held in Sweden marking the start of a long-term manufacturing agreement between Cambrex — manufacturer of small molecule innovator and active pharmaceutical ingredients — and AstraZeneca.
Opening
The commencement of this long-term agreement follows the completion of a large-scale, multi-purpose capacity expansion and a dedicated continuous flow production unit at Cambrex’s Karlskoga site in Sweden.
“Cambrex was selected as our manufacturing partner on this long-term intermediate supply agreement as they clearly demonstrated a robust technically and commercially attractive solution, as well as having a good track record in terms of performance and delivery,” said Juliette White, VP Global External Sourcing, AstraZeneca, “We look forward to a successful collaboration with Cambrex.”
Shawn Cavanagh, COO of Cambrex, stated: “We have an excellent relationship with AstraZeneca dating back to the 1950s and are excited to partner with them on the long-term production of several important products. We will continue to invest in capabilities, technology and appropriate capacity at the Karlskoga site in line with AstraZeneca’s ambitious targets and on-going customer demand.”
